Branched-chain amino acid supplementation in adults with cirrhosis and porto-systemic encephalopathy: Systematic review

Clinical Nutrition

Volumn 33, Issue 6, 2014, Pages 958-965

  Metcalfe, Emma Louise ^a,b   Avenell, Alison ^a   Fraser, Andrew ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Branched chain amino acids; Cirrhosis; Porto systemic encephalopathy

Indexed keywords

BRANCHED CHAIN AMINO ACID;

ARTICLE; ASCITES; DECOMPENSATED LIVER CIRRHOSIS; DIET SUPPLEMENTATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEPATIC ENCEPHALOPATHY; HEPATITIS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LIVER CIRRHOSIS; META ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; LENGTH OF STAY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

AMINO ACIDS, BRANCHED-CHAIN; DIETARY SUPPLEMENTS; HEPATIC ENCEPHALOPATHY; HUMANS; LENGTH OF STAY; LIVER CIRRHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84920136529     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2014.02.011     Document Type: Article

References (47)

1. Sheron N., Olsen N., Gilmore I. An evidence based alcohol policy. Gut 2008, 57:1341-1344.
2. Ekstedt M., Franzen L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
3. The European health report 2009. Health & health systems 2009, WHO, The World Health Organisation. http://www.euro.who.int.
4. National Liver Plan Atime to act: improving liver health and outcomes in liver disease 2009, The National Plan for Liver Services UK. http://www.bsg.org.uk.
5. Amodio P., Del Piccolo F., Petteno E., Mapelli D., Angeli P., Lemmolo R., et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. JHepatol 2001, 35:37-45.
6. Ortiz M., Jacas C., Cordoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. JHepatol 2005, 42(Suppl.1):S45-S53.
7. Bustamante J., Rimola A., Ventura P.J., Nasava M., Cirera I., Reggiardo V., et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. JHepatol 1999, 30:890-895.
8. Plauth M., Merli J., Kondrup J., Weimann A., Ferenci P., Müller M.J. Consensus statement: ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr 1997, 16:43-55.
9. Charlton M. Branched-chain amino acids: metabolism, physiological function, and application: branched-chain amino acid enriched supplements as therapy for liver disease. JNutr 2006, (Suppl.):S295-S298.
10. Fischer J.E., Baldessarini R.J. False neurotransmitters and hepatic failure. Lancet 1971, 2:75-79.
11. Marchesini G., Bianchi G., Rossi B., Brizi M., Melchionda N. Nutritional treatment with branched-chain amino acids in advanced liver disease. JGastroenterol 2000, 35(Suppl.XII):7-12.
12. Sax H.C., Talamini M.A., Fischer J.E. Clinical use of branched-chain amino acids in liver disease, sepsis, trauma, and burns. Arch Surg 1986, 121:358-366.
13. Laviano A., Muscaritoli M., Cascino A., Preziosa I., Inui A., Mantovani G., et al. Branched-chain amino acids: the best compromise to achieve anabolism?. Curr Opin Clin Nutr Metab Care 2005, 8:408-414.
14. Iwasa M., Matsumura K., Watanabe Y., Yamamoto M., Kaito M., Ikoma J., et al. Improvement of regional cerebral blood flow after treatment with branched-chain amino acid solutions in patients with cirrhosis. Eur J Gastroenterol Hepatol 2003, 15:733-737.
15. Yamamoto M., Iwasa M., Matsumura K., Nakagawa Y., Fujita N., Kobayashi Y., et al. Improvement of regional cerebral blood flow after oral intake of branched-chain amino acids in patients with cirrhosis. World J Gastroenterol 2005, 11(43):6792-6799.
16. Marchesini G., Bianchi G., Merli M., Amodio P., Panella C., Loguercio C., et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomised trial. Gastroenterology 2003, 124(7):1792-1801.
17. Muto Y., Sato S., Watanabe A., Moriwaki H., Suzuki K., Kato A., et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005, 3(7):705-713.
18. Kawamura E., Habu D., Morikawa H., Enomoto M., Kawabe J., Tamori A., et al. Arandomised pilot trial of oral branched-chain amino acids in early cirrhosis: validation using prognostic markers for pre-liver transplant status. Liver Transpl 2009, 15:790-797.
19. Naylor D.C., O'Rourke K., Detsky A.S., Baker J.P. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. Gastroenterology 1989, 97:1033-1042.
20. Als-Nielsen B., Koretz R.L., Gluud L., Gluud C. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev 2003, (1):CD001939.
21. Plauth M., Cabre E., Riggio O., Assis-Camilo M., Pirlich M., Kondrup J., et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr 2006, 25:285-294.
22. Plauth M., Cabré E., Campillo B., Kondrup J., Marchesini G., Schütz T., et al. ESPEN guidelines on parenteral nutrition: hepatology. Clin Nutr 2009, 28:436-444.
23. Higgins J.P.T., Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (Updated March 2011) 2011, The Cochrane Collaboration. http://www.cochrane-handbook.org.
24. Eriksson L.S., Persson A., Wahren J. Branched-chain amino acids in the treatment of chronic hepatic encephalopathy. Gut 1982, 23:801-806.
25. Fiaccadori F., Elia G.F., Lehndorff H., Merli M., Pedretti G., Riggio O., et al. The effect of dietary supplementation with branched-chain amino acids (BCAAs) versus casein in patients with chronic recurrent portal systemic encephalopathy: a controlled trial. Advances in ammonia metabolism and hepatic encephalopathy 1988, 489-497. Excerpta Medica, Oxford. P. Soeters, J. Wilson (Eds.).
26. Hasse J., Crippin J., Blue L., Huang K., DiCecco S., Francisco-Ziller N., et al. Does nutrition supplementation benefit liver transplant candidates with a history of encephalopathy? (Abstract). JParenter Enter Nutr 1997, 21(1). S16(91).
27. Hayashi S., Aoyagi Y., Oka H., Oda T. Arandomised controlled trial of branched-chain amino acid (BCAA) enriched elemental diet (ED-H) for hepatic encephalopathy. (Abstract). JGastroenterol Hepatol 1991, 6(2):191. And, unpublished data: Hayashi S, Aoyagi Y, Oka H & Oda T (1991). A randomised controlled study of an elementary diet (ED-H) in cirrhotics with hepatic encephalopathy.
28. Horst D., Grace N.D., Conn H.O., Schiff E., Schenker S., Viteri A., et al. Comparison of dietary protein with an oral branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomised controlled trial. Hepatology 1984, 4(2):279-287.
29. Les I., Doval E., Garcia-Martinez R., Planas M., Cardenas G., Gómez P., et al. Effects of branched-chain amino acid supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomised study. Am J Gastroenterol 2011, 106(6):1081-1088.
30. Marchesini G., Dioguardi F.S., Bianchi G.P., Zoli M., Bellati G., Roffi L., et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomised double-blind casein-controlled trial. JHepatol 1990, 11:92-101.
31. Panella C., Guglielmi F., Laddaga L., Reale L., Polimeno L., DiLeo A., et al. Oral branched-chain amino acids in the treatment of low portosystemic encephalopathy: a long term multicentric trial. Liver and Hormones Meeting, Bari, Italy. Nov 19-21 (1986) XVI+356P 1987, vol. 43:97-106. Raven Press, New York, USA, ILLUS. A. Francavilla (Ed.).
32. Tschepe A., Holm E., Leweling H., Staedt U., Weber K. Oral administration of branched chain amino acids (BCAA) in patients with liver cirrhosis (Abstract). A double-blind, randomised crossover study. Clin Nutr 1985, 4(Special Suppl.):40.
33. Ferenci P., Lockwood A., Mullen K., Tarter R., Weissenborn K., Blei A.T. Hepatic encephalopathy - definition, nomenclature, diagnosis and quantification: final report of the Working Party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 2002, 35(3):716-720.
34. Amodio P., Bemeur C., Butterworth R., Cordoba J., Kato A., Montagnese S., et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: international society for hepatic encephalopathy and nitrogen metabolism consensus. Hepatology 2013, 58(1):325-336.
35. Hayaishi S., Chung H., Kudo M., Ishikawa E., Takita M., Ueda T., et al. Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis. Dig Dis 2011, 29:326-332.
36. British national formulary, vol. 61; 2011 http://www.bnf.org.
37. Als-Nielsen B., Gluud L., Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004, 328:1046-1051.
38. Bass N.M. Review article: the current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther 2006, 25(Suppl.1):23-31.
39. Huang E., Esrailian E., Spiegal B.M.R. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Aliment Pharmacol Ther 2007, 26:1147-1161.
40. NICE. National Institute for Health & Clinical Excellence. Hepatic encephalopathy - rifaximin (maintenance) [ID496] http://guidance.nice.org.uk/TAG/297.
41. IDIS Pharma. http://www.idispharma.com.
42. Ferenci P., Lockwood A., Mullen K., Tarter R., Weissenborn K., Blei A. Hepatic encephalopathy - definition, nomenclature, diagnosis and quantification: final report of the Working Party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 2002, 35(3):716-720. the Members of the Working Party.
43. Mullen K. Review of the final report of the 1998 Working Party on the definition, nomenclature and diagnosis of hepatic encephalopathy. Aliment Pharmacol Ther 2006, 25(Suppl.):11-16.
44. Child C.G., Turcotte J.G. Surgery and portal hypertension. The liver and portal hypertension 1964, 50-64. Saunders, Philadelphia. C.G. Child (Ed.).
45. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60(8):646-649.
46. Jung G.E., Encke J., Schmidt J., Rahmel A. The model for end-stage liver disease (MELD). Hepatology 2007, 45(3):797-805.
47. EQ-5D. EuroQol-5D. A standardised instrument for use as a measure of health outcome. http://www.euroqol.org.